Online prescriptions – for everything from weight loss to medicinal cannabis – is now a big business backed by Woolworths and ...

Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...

President Donald Trump also threatened a 25-percent tariff on Apple products unless iPhones are made in the US.

NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid ...

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient ...

As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.

A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to ...

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

Plus, peek inside Raleigh’s newest data center, a Duke researcher reflects on her canceled federal grant amid buyouts, and ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Procurement Magazine takes a look back at the biggest news from across the industry over the last seven days, including SAP, ...